非小细胞肺癌阳性胸水BRAF^(V600E)基因突变的研究

The research of BRAF^(V600E) gene mutations in positive pleural effusion of non-small cell lung cancer

目的分析BRAFV600E基因突变在非小细胞肺癌阳性胸水中的表达情况。方法将胸水内查见肺腺癌细胞的病例24例其阳性胸水离心沉渣制作细胞块。分离细胞块样品DNA,使用扩增突变系统(ARMS)方法进行PCR扩增,检测BRAFV600E基因突变情况。结果检测成功率为100%,突变检出率为8%,检出突变2例,男性及女性各1例,FAM信号Ct值分别为18.7及17.8,STD的FAM信号Ct值为18。结论可以应用非小细胞肺癌阳性胸水代替肺癌肿瘤组织检测BRAFV600E基因突变,对指导晚期非小细胞肺癌病人靶向药物治疗具有重要指导意义。

Objective To investigate the BRAFV600 Emutation in positive pleural effusion of non-small cell lung cancer（NSCLC）.Methods 24 patients with the pleural effusion including lung adenocarcinoma cancer cells were selected,whose positive pleural effusion was made for cell blocks by centrifugal sediment.DNA in cell blocks was separated to amplify DNA by the method of amplification refractory mutation system（ARMS）and detect gene mutations of BRAFV600 E.Results Test success rate was 100% and mutation detection rate was 8%.2cases mutation were checked out,of which men and women each 1case.FAM signal Ct value were respectively 18.7and 17.8,STD FAM signals of Ct value was 18.Conclusion NSCLC positive pleural effusion could take the place of tumor tissue to detect BRAFV600 Egene mutation,which was obviously important to guide the targeted drugs in terminal NSCLC patients.